JD Health International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

JD Health International şirketinin toplam hissedar öz sermayesi CN¥52.1B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥67.2B ve CN¥15.1B dir. JD Health International 'in FAVÖK'ü CN¥786.6M faiz karşılama oranı -0.4 dur. Şirketin CN¥47.9B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-0.4x
Nakit	CN¥47.92b
Eşitlik	CN¥52.14b
Toplam yükümlülükler	CN¥15.08b
Toplam varlıklar	CN¥67.22b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 8ZN 'nin kısa vadeli varlıkları ( CN¥55.0B ) kısa vadeli yükümlülüklerini ( CN¥14.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 8ZN şirketinin kısa vadeli varlıkları ( CN¥55.0B ) uzun vadeli yükümlülüklerini ( CN¥371.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 8ZN borçsuzdur.

Borcun Azaltılması: 8ZN şirketinin 5 yıl önce borç/öz sermaye oranı 2506.4% iken borcu yok.

Borç Kapsamı: 8ZN un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 8ZN şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

JD Health International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 28% overvalued after recent price rise

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 15%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold €625k worth of stock

Now 25% undervalued after recent price drop

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold €24m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin